Major Everest rule change planned to only permit climbers who have scaled at least one 7,000m peak - New bill criticised by ...

NEFECON®, as the only approved IgAN therapy in China, generated RMB353.4 million in revenue for the year, representing a year-over-year increase of 1,581%. NEFECON® was also included in China’s ...